arXiv AI
Responsible Integration of AI in Cancer Genomics: Barriers, Risks, and Pathways to Trustworthy Clinical Translation
Read the original on arXiv AI →The Flow has not summarised this story yet — read it at arXiv AI.
Related stories
Hugging Face Trending Papers
4d ago
Responsible Integration of AI in Cancer Genomics: Barriers, Risks, and Pathways to Trustworthy Clinical Translation
Artificial intelligence (AI) and natural language processing (NLP) are increasingly used to extract, integrate, and interpret biomedical knowledge relevant to cancer genomics, yet their translation in...
arXiv AI
Jun 4
Breaking Bad Molecules: Are MLLMs Ready for Structure-Level Molecular Detoxification?
arXiv:2506. 10912v4 Announce Type: replace Abstract: Toxicity remains a leading cause of early-stage drug development failure.
arXiv AI
3d ago
From Analytics to Tumor Boards: An Evidence-Linked Multi-Agent Workflow for Oncology Feature Extraction
arXiv:2608.28974v1 Announce Type: new Abstract: Clinically relevant oncology information is distributed across heterogeneous, longitudinal documentation, creating substantial abstraction burden and r...
Hugging Face Trending Papers
Aug 24
LUCAID: Agentic Multimodal AI for Lung Cancer Precision Pathology
Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological asses...
arXiv AI
Aug 25
Dissecting Neuro-Symbolic Quality Assurance for Synthetic Oncology Data Generation
arXiv:2608.22085v1 Announce Type: new Abstract: Synthetic clinical data generation with large language models addresses the scarcity that limits cancer staging research, but oncology hallucinations a...
arXiv AI
Aug 26
LUCAID: Agentic Multimodal AI for Lung Cancer Precision Pathology
LUCAID is an agentic multimodal AI system designed for precision lung cancer pathology, integrating nine modules that cover the entire routine workflow—from quality control and tumor detection to histological subtyping, microenvironment profiling, cellularity quantification, and biomarker scoring (PD‑L1, MET, TROP‑2). The system generates automated structured reports and allows interactive querying of module outputs. In prospective clinical validation, LUCAID achieved 93.0% concordance with an expert‑panel reference standard for clinically actionable decisions, outperforming five experienced thoracic pathologists who ranged from 68.3% to 81.1% concordance.